Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study

Journal of the International Neuropsychological Society

Volumn 21, Issue 8, 2015, Pages 573-583

  Aschenbrenner, Andrew J ^a   Balota, David A ^a,b   Fagan, Anne M ^b   Duchek, Janet M ^a   Benzinger, Tammie L S ^a,b,c   Morris, John C ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Amyloid; Attention; Biological markers; Episodic memory; Longitudinal study

Indexed keywords

2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; BIOLOGICAL MARKER; THIAZOLE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CEREBROSPINAL FLUID; COMPLICATION; DIAGNOSTIC IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISODIC MEMORY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PSYCHOLOGICAL RATING SCALE;

AGED; ALZHEIMER DISEASE; ANILINE COMPOUNDS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY DISORDERS; MEMORY, EPISODIC; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; THIAZOLES;

EID: 84944457266     PISSN: 13556177     EISSN: 14697661     Source Type: Journal    
DOI: 10.1017/S1355617715000776     Document Type: Article

References (69)

1. Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C.,Mathis, C.A., Tsopelas, N.D., ⋯ Klunk, W.E. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology, 65, 1509-1517. doi:10.1001/archneur.65.11.1509
2. Aschenbrenner, A.J., Balota, D.A., Tse, C.S., Fagan, A.M., Holtzman, D.M., Benzinger, T.L., & Morris, J.C. (2015). Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. Neuropsychology, 29, 368-381.
3. Balota, D.A., & Duchek, J.M. (2015). Attention, variability, and biomarkers in Alzheimer's disease. In Remembering: Attributions, processes, and control in human memory (pp. 285-303). New York: Psychology Press.
4. Balota, D.A., & Faust, M. (2001). Attention in Dementia of the Alzheimers Type. In F. Boller & S. Cappa (Eds.), Handbook of Neuropsychology (2nd ed., Vol. 6, pp. 51-80). New York: Elsevier Science.
5. Balota, D.A., Tse, C.S., Hutchison, K.A., Spieler, D.H., Duchek, J.M., & Morris, J.C. (2010). Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: The power of errors in Stroop color naming. Psychology and Aging, 25, 208-218. doi:10.1037/a0017474
6. Banich, M.T., Milham, M.P., Atchley, R., Cohen, N.J., Webb, A., Wszalek, T., ⋯ Magin, R. (2000). fMri studies of Stroop tasks reveal unique roles of anterior and posterior brain systems in attentional selection. Journal of Cognitive Neuroscience, 12, 988-1000.
7. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C.,⋯Morris, J.C. (2012). Clinical and biomarker changes in dominantly inheritedAlzheimer's disease. New England Journal of Medicine, 367, 795-804. doi:10.1056/NEJMoa1202753
8. Bates,D., Maechler,M., Bolker, B., & Walker, S. (2014). lme4: Linear mixed-effects models using Eigen and S4. R package version 1.1-7. Retrieved from http://CRAN.R-project.org/packagelme4
9. Bertens, D., Knol, D.L., Scheltens, P., & Visser, P.J. (2015). Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimer's & Dementia, 11, 511-522. doi:10.1016/j.jalz.2014.05.1754
10. Buckner, R.L., Snyder, A.Z., Shannon, B.J., LaRossa, G., Sachs, R., Fotenos, A.F., ⋯ Mintun, M.A. (2005). Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience, 25(34), 7709-7717. doi:10.1523/JNEUROSCI.2177-05.2005
11. Castel, A.D., Balota, D.A., Hutchison, K.A., Logan, J.M., & Yap, M.J. (2007). Spatial attention and response control in healthy younger and older adults and individuals with Alzheimer's disease: Evidence for disproportionate selection impairments in the Simon task. Neuropsychology, 21, 170-182. doi:10.1037/0894-4105.21.2.170
12. Craig-Schapiro, R., Perrin, R.J., Roe, C.M., Xiong, C., Carter, D., Cairns,N.J., ⋯Holtzman, D.M. (2010).YKL-40:Anovel prognostic fluid biomarker for preclinical Alzheimer's disease. Biological Psychiatry, 68(10), 903-912. doi:10.1016/j.biopsych.2010.08.025
13. Craik, F.I.M., & Lockhart, R.S. (1972). Levels of processing: A framework for memory research. Journal of Verbal Learning and Verbal Behavior, 11, 671-684.
14. Davison, A.C., & Hinkley, D.V. (1997). Bootstrap methods and their application. New York: Cambridge University Press.
15. Doraiswamy, P.M., Sperling, R.A., Coleman, R.E., Johnson, K.A., Reiman, E.M., Davis, M.D., ⋯ Pontecorvo, M.J. (2012). Amyloid-Assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology, 79, 1636-1644. doi:10.1212/WNL.0b013e3182661f74
16. Duchek, J.M., Balota, D.A., Thomas, J.B., Snyder, A.Z., Rich, P., Benzinger, T.L., ⋯ Ances, B.M. (2013). Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults. Neuropsychology, 27(5), 516-528. doi:10.1037/a0033402
17. Duchek, J.M., Balota, D.A., Tse, C.S.,Holtzman, D.M., Fagan, A.M., & Goate, A.M. (2009). The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer's disease. Neuropsychology, 23(6), 746-758. doi:10.1037/a0016583
18. Ellis, K.A., Lim, Y.Y., Harrington, K., Ames, D., Bush, A.I., Darby, D., ⋯ Maruff, P. (2013). Decline in cognitive function over 18 months in healthy older adults with high amyloid-?. Journal of Alzheimer's Disease, 34(4), 861-871.
19. Ewers, M., Insel, P., Jagust, W.J., Shaw, L., Trojanowski, J.Q., Aisen, P., ⋯ Weiner, M.W. (2012). CSF biomarker and PIB-PET-derived beta-Amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cerebral Cortex, 22(9), 1993-2004. doi:10.1093/cercor/bhr271
20. Fagan, A.M., Mintun, M.A., Shah, A.R., Aldea, P., Roe, C.M., Mach, R.H., ⋯ Holtzman, D.M. (2009). Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Molecular Medicine, 1, 371-380. doi:10.1002/emmm.200900048
21. Fagan, A.M., Roe, C.M., Xiong, C., Mintun, M.A., Morris, J.C., & Holtzman, D.M. (2007). Cerebrospinal fluid tau/beta-Amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology, 64, 343-349. doi:10.1001/archneur.64.3.noc60123
22. Fischl, B. (2004). Automatically parcellating the human cerebral cortex. Cerebral Cortex, 14, 11-22.
23. Galvin, J.E., Powlishta, K.K., Wilkins, K., McKeel, D.W., Xiong, C., Grant, E., ⋯ Morris, J.C. (2005). Predictors of preclinical Alzheimer disease and dementia: A clinicopathologic study. Archives of Neurology, 62, 758-765.
24. Glodzik, L., de Santi, S., Tsui, W.H., Mosconi, L., Zinkowski, R., Pirraglia, E., ⋯ de Leon, M.J. (2011). Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiology of Aging, 32(12), 2131-2141. doi:10.1016/j.neurobiolaging.2009.12.026
25. Gordon, B.A., Zacks, J.M., Blazey, T., Benzinger, T.L., Morris, J.C., Fagan, A.M., ⋯Balota, D.A. (2015). Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. Neurobiology of Aging, 36, 1771-1779. doi:10.1016/j.neurobiolaging.2015.01.019
26. Grober, E., Buschke, H., Crystal, H., Bang, S., & Dresner, R. (1988). Screening for demenita by memory testing. Neurology, 38, 900-903.
27. Hedden, T., Oh, H., Younger, A.P., & Patel, T.A. (2013). Metaanalysis of amyloid-cognition relations in cognitively normal older adults. Neurology, 80, 1341-1348.
28. Kane, M.J., & Engle, R.W. (2002). The role of prefrontal cortex in working-memory capacity, executive attention, and general fluid intelligence: An individual-differences perspective. Psychonomic Bulletin & Review, 9(4), 637-671. doi:10.3758/BF03196323
29. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., ⋯ Långström, B. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 55(3), 306-319. doi:10.1002/ana.20009
30. Kuznetsova, A., Brockhoff, P.B., & Christensen, R.H.B. (2014). lmerT-est: Tests for random and fixed effects for linear mixed effects models (lmer objects of lme4 package). R Package Version 2.0-11. Retrieved from http://CRAN.R-project.org/packagelmerTest
31. Landau, S.M., Mintun, M.A., Joshi, A.D., Koeppe, R.A., Petersen, R.C., Aisen, P.S., ⋯ Jagust, W.J. (2012). Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology, 72(4), 578-586. doi:10.1002/ana.23650
32. Li, G., Millard, S.P., Peskind, E.R., Zhang, J., Yu, C.E., Leverenz, J.B., ⋯ Montine, T.J. (2014). Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA Neurology, 71(6), 742-751. doi:10.1001/jamaneurol.2014.445
33. Li, G., Sokal, I., Quinn, J.F., Leverenz, J.B., Brodey, M., Schellenberg, G.D., ⋯ Montine, T.J. (2007). CSF tau/A?42 ratio for increased risk of mild cognitive impairment A followup study. Neurology, 69, 631-639.
34. Lim, Y.Y., Pietrzak, R.H., Ellis, K.A., Jaeger, J., Harrington, K., Ashwood, T., ⋯ Maruff, P. (2013). Rapid decline in episodic memory in healthy older adults with high amyloid-?. Journal of Alzheimer's Disease, 33, 675-679. doi:10.3233/JAD-2012-121516
35. Lo, R.Y., Hubbard, A.E., Shaw, L.M., Trojanowski, J.Q., Peterson, R.C., Aisen, P.S., ⋯Jagust, W.J. (2011). Longitudinal change of biomarkers in cognitive decline. Archives of Neurology, 68(10), 1257-1266. doi:10.1001/archneurol.2011.123
36. Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S.D., Bernardini, S., ⋯ Blennow, K. (2011). The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia, 7, 386-395e6. doi:10.1016/j.jalz.2011.05.2243
37. McCabe, D.P., Roediger, H.L., McDaniel, M.A., Balota, D.A., & Hambrick, D.Z. (2010). The relationship between working memory capacity and executive functioning: Evidence for a common executive attention construct. Neuropsychology, 24(2), 222-243. doi:10.1037/a0017619
38. Mintun, M.A., LaRossa, G.N., Sheline, Y.I., Dence, C.S., Lee, S.Y., Mach, R.H., ⋯Morris, J.C. (2006). [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology, 67, 446-452. doi:10.1212/01.wnl.0000228230.26044.a4
39. Morris, J.C. (1993). The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology, 43, 2412-2414.
40. Morris, J.C., McKeel, D.W., Storandt, M., Rubin, E.H., Price, J.L., Grant, E.A., ⋯ Berg, L. (1991). Very mild Alzheimer's disease: Informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology, 41, 469-478.
41. Mungas, D., Tractenberg, R., Schneider, J.A., Crane, P.K., & Bennett, D.A. (2014). A 2-process model for neuropathology of Alzheimer's disease. Neurobiology of Aging, 35, 301-308. doi:10.1016/j.neurobiolaging.2013.08.007
42. Nebes, R.D., Snitz, B.E., Cohen, A.D., Aizenstein, H.J., Saxton, J.A., Halligan, E.M., ⋯Klunk, W.E. (2013). Cognitive aging in persons with minimal amyloid-? and white matter hyperintensities. Neuropsychologia, 51, 2202-2209. doi:10.1016/j.neuropsychologia. 2013.07.017
43. Perry, R.J., & Hodges, J.R. (1999). Attention and executive deficits in Alzheimer's disease: A critical review. Brain: A Journal of Neurology, 122, 383-404.
44. Price, J.L., McKeel, D.W., Buckles, V.D., Roe, C.M., Xiong, C., Grundman, M., ⋯ Morris, J.C. (2009). Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging, 30, 1026-1036. doi:10.1016/j.neurobiolaging.2009.04.002
45. Resnick, S.M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D.P., ⋯ Wong, D.F. (2010). Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology, 74, 807-815.
46. Rodrigue, K.M., Kennedy, K.M., Devous, M.D., Rieck, J.R., Hebrank, A.C., Diaz-Arrasita, R., ⋯ Park, D.C. (2012). B-Amyloid burden in healthy aging: Regional distribution and cognitive consequences. Neurology, 78, 387-395.
47. Roe, C.M., Fagan, A.M., Grant, E.A., Hassenstab, J., Moulder, K. L., Dreyfus, D.M., ⋯Morris, J.C. (2013). Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology, 80, 1784-1791.
48. Rolstad, S., Berg, A.I., Bjerke, M., Johansson, B., Zetterberg, H., & Wallin, A. (2013). Cerebrospinal fluid biomarkers mirror rate of cognitive decline. Journal of Alzheimer's Disease, 34, 949-956. doi:10.3233/JAD-121960
49. Simon, J.R. (1969). Reactions toward the source of stimulation. Journal of Experimental Psychology, 81, 174-176.
50. Snijders, T., & Bosker, R. (1999). Multilevel Analysis: An introduction to basic and advanced multilevel modeling. Thousand Oaks, CA: SAGE Publications.
51. Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., ⋯ Phelps, C.H. (2011). Toward defining the preclinical stages of Alzheimer's disease: Recommendations from theNational Institute on Aging-Alzheimer'sAssociationworkgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7, 280-292. doi:10.1016/j.jalz.2011.03.003
52. Sperling, R.A., Johnson, K.A., Doraiswamy, P.M., Reiman, E.M., Fleisher, A.S., Sabbagh, M.N., ⋯ Pontecorvo, M.J. (2013). Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging, 34, 822-831. doi:10.1016/j.neurobiolaging.2012.06.014
53. Spieler, D.H., Balota, D.A., & Faust, M.E. (1996). Stroop performance in healthy younger and older adults and in individuals with dementia of the Alzheimer's type. Journal of Experimental Psychology: Human Perception and Performance, 22, 461-479.
54. Stern, Y. (2009). Cognitive reserve. Neuropsychologia, 47, 2015-2028. doi:10.1016/j.neuropsychologia.2009.03.004
55. Stomrud, E., Hansson, O., Zetterberg, H., Blennow, K., Minthon, L.,& Londos, E. (2010). Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Archives of Neurology, 67(2), 217-223.
56. Storandt,M., Head, D., Fagan, A.M., Holtzman, D.M.,&Morris, J.C. (2012). Toward a multifactorial model of Alzheimer disease. Neurobiology of Aging, 33, 2262-2271. doi:10.1016/j.neurobiolaging.2011.11.029
57. Storandt, M., & Hill, R.D. (1989). Very mild senile dementia of the Alzheimer type II: Psychometric test performance. Archives of Neurology, 46, 383-386.
58. Storandt, M., Mintun, M.A., Head, D., & Morris, J.C. (2009). Cognitive decline and brain volume loss as signatures of cerebral amyloid-? peptide deposition identified with Pittsburgh compound B. Archives of Neurology, 66, 1476-1481. doi:10.1001/archneurol.2009.272
59. Stroop, J.R. (1935). Studies of interference in serial verbal reactions. Journal of Experimental Psychology, 18, 643-662. doi:10.1037/h0054651
60. Su, Y., D'Angelo, G.M., Vlassenko, A.G., Zhou, G., Snyder, A.Z., Marcus, D.S., ⋯ Benzinger, T.L. (2013). Quantitative analysis of PiB-PET with Freesurfer ROIs. PLoS One, 8, e73377.
61. Tse, C.S., Balota, D.A., Yap, M.J., Duchek, J.M., & McCabe, D.P. (2010). Effects of healthy aging and early stage dementia of the Alzheimer's type on components of response time distributions in three attention tasks. Neuropsychology, 24, 300-315. doi:10.1037/a0018274
62. Twamley, E.W., Ropacki, S.A., & Bondi, M.W. (2006). Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. Journal of the International Neuropsychological Society, 12, 707-735.
63. Vanderhasselt, M.A., De Raedt, R., & Baeken, C. (2009). Dorsolateral prefrontal cortex and Stroop performance: Tackling the lateralization. Psychonomic Bulletin & Review, 16(3), 609-612. doi:10.3758/PBR.16.3.609
64. Vemuri, P., Wiste, H.J., Weigand, S.D., Shaw, L.M., Trojanowski, J.Q., Weiner, M.W., ⋯ Jack, C.R. (2009). MRI and CSF biomarkers in normal, MCI, and AD subjects Diagnostic discrimination and cognitive correlations. Neurology, 73, 287-293. doi:10.1212/WNL.0b013e3181af79e5
65. Villemagne, V.L., Pike, K.E., Chételat, G., Ellis, K.A.,Mulligan, R.S., Bourgeat, P., ⋯ Rowe, C.C. (2011). Longitudinal assessment of A? and cognition in aging and Alzheimer disease. Annals of Neurology, 69(1), 181-192. doi:10.1002/ana.22248
66. Vos, S.J., Xiong, C., Visser, P.J., Jasielec, M.S., Hassenstab, J., Grant, E.A., ⋯ Fagan, A.M. (2013). Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study. The Lancet Neurology, 12, 957-965.
67. Wechsler, D. (1987). Weschler Memory Scale: Administration and Scoring manual (3rd ed.). San Antonio, TX: Psychological Corporation.
68. Wechsler, D., & Stone, C.P. (1973). Manual: Wechsler Memory Scale. New York: Psychological Corporation.
69. Xiong, C., Roe, C.M., Buckles, V., Fagan, A., Holtzman, D., Balota, D., ⋯ Morris, J.C. (2011). Role of family history for Alzheimer biomarker abnormalities in the Adult Children Study. Archives of Neurology, 68(10), 1313-1319.